Physician profile
Sheetal B Desai
NPI 1699966861
$491,999.43
in general payments reported to CMS, 2019-2025
19 companies · $80K in 2025
The $80K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $36K · 2021: $80K · 2022: $95K · 2023: $74K · 2024: $98K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Consulting Fee: $96K · Travel and Lodging: $53K · Food and Beverage: $4,873 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,922.35 |
| Consulting Fee | $95,703.34 |
| Travel and Lodging | $52,656.32 |
| Food and Beverage | $4,872.87 |
| Education | $148.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146,688.12 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $102,103.02 | 2019-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $66,158.93 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Aurinia Pharma U.S., INC. | $63,948.13 | 2021-2025 | Lupkynis |
| Astrazeneca Uk Limited | $57,236.35 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $38,237.70 | 2019-2025 | Simponi Aria, Tremfya |
| Alexion Pharmaceuticals, INC. | $6,677.80 | 2022 | |
| Sobi, INC | $3,140.83 | 2025 | |
| Biogen, INC. | $2,756.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,699.67 | 2025 | |
| Ucb, INC. | $1,893.33 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $134.44 | 2024 | |
| Abbvie INC. | $111.39 | 2022 | |
| Genzyme Corporation | $83.71 | 2024 | |
| Pfizer INC. | $77.73 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.47 | 2022 | |
| Novo Nordisk INC | $25.81 | 2025 | Ozempic |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.